» Articles » PMID: 28231277

Comparison of Cross-sectional HIV Incidence Assay Results from Dried Blood Spots and Plasma

Abstract

Background: Assays have been developed for cross-sectional HIV incidence estimation using plasma samples. Large scale surveillance programs are planned using dried blood spot (DBS) specimens for incidence assessment. However, limited information exists on the performance of HIV cross-sectional incidence assays using DBS.

Methods: The assays evaluated were: Maxim HIV-1 Limiting Antigen Avidity EIA (LAg-Avidity), Sedia HIV-1 BED-Capture EIA (BED-CEIA), and CDC modified BioRad HIV-1/2 Plus O Avidity-based Assay (CDC-BioRad Avidity) using pre-determined cutoff values. 100 matched HIV-1 positive plasma and DBS samples, with known duration of infection, from the Consortium for the Evaluation and Performance of HIV Incidence Assays repository were tested. All assays were run in duplicate. To examine the degree of variability within and between results for each sample type, both categorical and continuous results were analyzed. Associations were assessed with Bland Altman, R2 values and Cohen's kappa coefficient (ĸ).

Results: Intra-assay variability using the same sample type was similar for all assays (R2 0.96 to 1.00). The R2 values comparing DBS and plasma results for LAg-Avidity, BED-CEIA, and CDC-BioRad Avidity were 0.96, 0.94, and 0.84, respectively. The concordance and ĸ values between DBS and plasma for all three assays were >87% and >0.64, respectively. The Bland-Altman analysis showed significant differences between plasma and DBS samples. For all three assays, a higher number of samples were classified as recent infections using DBS samples.

Conclusions: DBS and plasma sample results were highly correlated. However, when compared to plasma, each assay performed somewhat differently in DBS at the lower and higher ends of the dynamic range. DBS samples were more likely to be classified as recently infected by all three assays, which may lead to overestimation of incidence in surveys using performance criteria derived for plasma samples.

Citing Articles

Use of Next-Generation Sequencing in a State-Wide Strategy of HIV-1 Surveillance: Impact of the SARS-COV-2 Pandemic on HIV-1 Diagnosis and Transmission.

Zhou S, Long N, Moeser M, Hill C, Samoff E, Mobley V J Infect Dis. 2023; 228(12):1758-1765.

PMID: 37283544 PMC: 10733719. DOI: 10.1093/infdis/jiad211.


A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications.

Lau J, Murdock N, Murray J, Justman J, Parkin N, Miller V J Virus Erad. 2022; 8(3):100085.

PMID: 36124229 PMC: 9482108. DOI: 10.1016/j.jve.2022.100085.


Use of HIV Recency Assays for HIV Incidence Estimation and Other Surveillance Use Cases: Systematic Review.

Facente S, Grebe E, Maher A, Fox D, Scheer S, Mahy M JMIR Public Health Surveill. 2022; 8(3):e34410.

PMID: 35275085 PMC: 8956992. DOI: 10.2196/34410.


Experiences and lessons learned from the real-world implementation of an HIV recent infection testing algorithm in three routine service-delivery settings in Kenya and Zimbabwe.

de Wit M, Rice B, Risher K, Welty S, Waruiru W, Magutshwa S BMC Health Serv Res. 2021; 21(1):596.

PMID: 34158047 PMC: 8220670. DOI: 10.1186/s12913-021-06619-6.


Very High HIV Incidence and Associated Risk Factors in a Longitudinal Cohort Study of Diverse Adolescent and Young Adult Men Who Have Sex with Men and Transgender Women.

Mustanski B, Ryan D, Newcomb M, DAquila R, Matson M AIDS Behav. 2019; 24(6):1966-1975.

PMID: 31858300 PMC: 8560086. DOI: 10.1007/s10461-019-02766-4.


References
1.
Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong J, Hu D . Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses. 2010; 26(1):61-71. DOI: 10.1089/aid.2009.0133. View

2.
Kassanjee R, McWalter T, Barnighausen T, Welte A . A new general biomarker-based incidence estimator. Epidemiology. 2012; 23(5):721-8. PMC: 3500970. DOI: 10.1097/EDE.0b013e3182576c07. View

3.
Barin F, Meyer L, Lancar R, Deveau C, Gharib M, Laporte A . Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol. 2005; 43(9):4441-7. PMC: 1234099. DOI: 10.1128/JCM.43.9.4441-4447.2005. View

4.
Dobbs T, Kennedy S, Pau C, McDougal J, Parekh B . Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol. 2004; 42(6):2623-8. PMC: 427871. DOI: 10.1128/JCM.42.6.2623-2628.2004. View

5.
Busch M, Pilcher C, Mastro T, Kaldor J, Vercauteren G, Rodriguez W . Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS. 2010; 24(18):2763-71. DOI: 10.1097/QAD.0b013e32833f1142. View